There are currently 103 active clinical trials seeking participants for Glioblastoma research studies. The states with the highest number of trials for Glioblastoma participants are California, Ohio, New York and Texas.
Clinical Trial of the ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Recurrent Brain Tumors
Recruiting
The purpose of this study is to test WSD0628 in combination with radiation therapy for recurrent brain tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/06/2024
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Glioblastoma
Evaluation of the CONVIVO System
Recruiting
The primary objective of this study is to evaluate the diagnostic performance of the CONVIVO confocal endomicroscope in discriminating between normal and abnormal tissue in vivo during brain tumor surgery. The interpretation of intraoperative images obtained in situ will be tested against conventional histologic evaluation of targeted biopsies from imaged tissue. The study team hypothesize that there will be a high degree of correlation between images obtained with the CONVIVO system and convent... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2024
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Glioblastoma, Glial Tumor, Brain Metastases, Meningioma, Schwannoma, Pituitary Tumor
CBT-I in Primary Brain Tumor Patients: Phase IIc Randomized Feasibility Pilot Trial
Recruiting
This study seeks to investigate an evidence-based, manualized, behavioral health intervention, Cognitive Behavioral Therapy for Insomnia (CBT-I), in individuals with primary brain tumors (PBT) and insomnia. Our project will assess the feasibility and acceptability of recruitment, enrollment, data collection procedures, and retention of individuals with PBT and insomnia in the behavioral health intervention, CBT-I, and investigate the potential benefits of CBT-I within this at-risk and understudi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2024
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Primary Brain Tumor, Glioblastoma, Astrocytoma, Oligodendroglioma, Meningioma, Primary Central Nervous System (CNS) Lymphoma
Tofacitinib in Recurrent GBM Patients
Recruiting
The purpose of this study is to examine the effects of Tofacitinib in patients with recurrent Glioblastoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/03/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Glioblastoma
Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma
Recruiting
The purpose of this study is to find out if performing additional Magnetic Resonance Image (MRI) scans of the subjects' brain during each week of the radiation treatment of their high-grade glioma will help improve the radiation treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/28/2024
Locations: Columbia University Irving Medical Center/NYPH, New York, New York
Conditions: Glioblastoma, Anaplastic Astrocytoma, Astrocytoma, Anaplastic Oligodendroglioma
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
Recruiting
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2024
Locations: University of California, Los Angles (UCLA) Department of Medicine - Hematology/Oncology, Los Angeles, California +4 locations
Conditions: Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer, Glioblastoma, Pancreatic Cancer
Feasibility of Intraoperative Microdialysis During Neurosurgery for Central Nervous System Malignancies
Recruiting
This clinical trial evaluates the use of microdialysis catheters during surgery to collect biomarkers, and studies the feasibility of intraoperative microdialysis during neurosurgery for central nervous system malignancies. A biomarker is a measurable indicator of the severity or presence of disease state. Information collected in this study may help doctors to develop new strategies to better diagnose, monitor, and treat brain tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Diffuse Astrocytoma, Diffuse Glioma, Glioblastoma, Metastatic Malignant Neoplasm in the Brain, Oligodendroglioma
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
Recruiting
The purpose of this study is to find out how much tratuzumab deruxtecan (T-DXd) can penetrate the tumor when injected into the body, and whether T-DXd may be an effective treatment for brain cancers that express the HER2 protein.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/10/2024
Locations: Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York
Conditions: Brain Cancer, Glioblastoma, Metastatic Cancer, Leptomeningeal Metastasis, Recurrent Glioblastoma
Neoadjuvant Chemoradiation for Resectable Glioblastoma
Recruiting
Preoperative therapy has not been well studied in resectable glioblastoma. This study attempts to prospectively assess the feasibility and efficacy of preoperative chemo radiation in improving local control, as this is the predominant mode of failure in these patients leading to poor outcomes. This Phase II study design would be used to proceed with the study treatment after meeting pre-specified events in the initial phase, with goal being to determine whether the new treatment paradigm is suf... Read More
Gender:
All
Ages:
Between 18 years and 89 years
Trial Updated:
04/26/2024
Locations: Geisinger Medical Center, Danville, Pennsylvania +1 locations
Conditions: Glioblastoma, Surgery, High Grade Glioma
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
Recruiting
Prospective, open-label, dose-ranging, uncontrolled phase I/II study of Lurbinectedin in combination with irinotecan. The study will be divided into two stages: a Phase I dose escalation stage and a Phase II expansion stage.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/26/2024
Locations: Sarcoma Oncology Center, Santa Monica, California +21 locations
Conditions: Advanced Solid Tumors, Glioblastoma, Endometrial Carcinoma, Mesothelioma, Gastroenteropancreatic Neuroendocrine Tumor, SCLC, Gastric Carcinoma, Soft Tissue Sarcoma (Excluding GIST), Epithelial Ovarian Carcinoma, Pancreatic Adenocarcinoma, Colorectal Carcinoma, Neuroendocrine Tumors
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma
Recruiting
The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/16/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +7 locations
Conditions: Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, GBM
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Recruiting
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.
Gender:
All
Ages:
All
Trial Updated:
03/12/2024
Locations: Massive Bio, Inc, New York, New York
Conditions: Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver, Cancer of Stomach, Cancer Liver, Cancer of Rectum, Cancer of Kidney, Cancer of Esophagus, Cancer of Cervix, Cancer of Colon, Cancer of Larynx, Cancer, Lung, Cancer, Breast, Cancer, Advanced, Cancer Prostate, Cancer of Neck, Cancer of Skin, Neuroendocrine Tumors, Carcinoma, Mismatch Repair Deficiency, BRCA Gene Rearrangement, Non Hodgkin Lymphoma, Leukemia, Non Small Cell Lung Cancer, Cholangiocarcinoma, Glioblastoma, Central Nervous System Tumor, Melanoma, Urothelial Carcinoma, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Testicular Cancer, Breast Cancer, COVID, Myelofibrosis, Myeloproliferative Neoplasm, Myeloproliferative Disorders, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndromes